Kelleher Financial Advisors Makes New Investment in Danaher Corporation $DHR

Kelleher Financial Advisors bought a new position in shares of Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,198 shares of the conglomerate’s stock, valued at approximately $237,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after acquiring an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after buying an additional 612,154 shares in the last quarter. Generation Investment Management LLP increased its holdings in shares of Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after acquiring an additional 1,787,522 shares during the period. Invesco Ltd. raised its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after purchasing an additional 163,332 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 2.2%

NYSE DHR opened at $215.80 on Wednesday. The business’s fifty day moving average is $204.36 and its 200 day moving average is $200.64. The company has a market cap of $152.43 billion, a price-to-earnings ratio of 44.49, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.71 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s payout ratio is 26.39%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of research reports. Barclays lifted their target price on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Guggenheim reiterated a “buy” rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Cowen restated a “buy” rating on shares of Danaher in a research note on Wednesday, October 22nd. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Bank of America dropped their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $243.39.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.